{"id":15583,"date":"2021-11-25T14:45:36","date_gmt":"2021-11-25T13:45:36","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=15583"},"modified":"2021-11-25T14:45:36","modified_gmt":"2021-11-25T13:45:36","slug":"faisabilite-dune-association-brentuximab-vedotin-rituximab-cyclophosphamide-doxorubicine-et-prednisone-dans-le-lymphome-b-diffus-a-grandes-cellules-cd30","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/faisabilite-dune-association-brentuximab-vedotin-rituximab-cyclophosphamide-doxorubicine-et-prednisone-dans-le-lymphome-b-diffus-a-grandes-cellules-cd30\/","title":{"rendered":"Faisabilit\u00e9 d\u2019une association Brentuximab-Vedotin Rituximab Cyclophosphamide Doxorubicine et Prednisone dans le lymphome B diffus \u00e0 grandes cellules CD30+"},"content":{"rendered":"<p><em>Brentuximab vedotin in combination with rituximab, <\/em><em>cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas<\/em><\/p>\n<p>R\u00e9f :HematoStat.net : 1 (11) : V22<\/p>\n<p><a href=\"https:\/\/pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr\/32414850\/\">DOI: 10.3324\/haematol.2019.238675\u00a0<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas R\u00e9f :HematoStat.net : 1 (11) : V22 DOI: 10.3324\/haematol.2019.238675\u00a0<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[11],"tags":[],"ppma_author":[442],"class_list":["post-15583","post","type-post","status-publish","format-standard","hentry","category-veille-bibliographique","author-marion"],"aioseo_notices":[],"authors":[{"term_id":442,"user_id":2,"is_guest":0,"slug":"marion","display_name":"HematoStat.net (M)","avatar_url":{"url":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2024\/01\/favicon-hematoStat.png","url2x":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2024\/01\/favicon-hematoStat.png"},"first_name":"HematoStat.net (M)","last_name":"","user_url":"","description":""}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15583","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=15583"}],"version-history":[{"count":0,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15583\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=15583"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=15583"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=15583"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=15583"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}